Group 1 - Point72 Asset Management, led by Steven Cohen, has achieved a remarkable 131% cumulative return on its top 20 holdings over the past three years, significantly outperforming the S&P 500's 64% return [2] - The hedge fund reported an 18% return in the second quarter, showcasing its ability to navigate market trends, particularly in AI and biotech sectors [2] - Cohen's recent investment in Palisade Bio Inc, a clinical-stage biotech company, involves a $7.6 million position, representing a small 0.03% of his portfolio, indicating a strategic approach to identifying potential market opportunities [3] Group 2 - Palisade Bio recently completed a $138 million public offering to support Phase 2 trials for its lead drug PALI-2108, which targets ulcerative colitis, a chronic intestinal condition [4] - The stock of Palisade Bio has experienced a nearly 200% surge in the past month, with an additional 11% increase in pre-market trading, driven by investor interest in its autoimmune therapy developments [4] - Cohen's investment strategy reflects a focus on identifying inflection points in the market, suggesting that future investment opportunities may arise from the biotech sector, particularly in gut health therapies [5]

Group 1 - Advanced Micro Devices, Inc. (AMD) shares increased significantly by 34.2% to $221.10 in pre-market trading following a major agreement with OpenAI to deploy up to 6 gigawatts of AMD Instinct GPU power for AI infrastructure [1][2] - The initial phase of the agreement includes a rollout of 1 gigawatt of AMD Instinct MI450 GPUs scheduled for the second half of 2026, with plans for further expansions across multiple generations of AMD's data center chips [1]

Core Viewpoint - Premarket trading is showing notable activity with significant price movements indicating potential investment opportunities before the market opens [1] Premarket Gainers - Society Pass Incorporated (SOPA) has increased by 139% to $3.34 - Critical Metals Corp. (CRML) has risen by 79% to $14.30 - Sanmina Corporation (SANM) is up 26% at $144.61 - Palisade Bio, Inc. (PALI) has gained 25% to $2.00 - Advanced Micro Devices, Inc. (AMD) has increased by 24% to $205.07 - Odyssey Marine Exploration, Inc. (OMEX) is up 22% at $2.46 - Youxin Technology Ltd (YAAS) has risen by 21% to $3.14 - NioCorp Developments Ltd. (NB) is up 18% at $9.38 - Snow Lake Resources Ltd. (LITM) has increased by 14% to $5.66 - Plug Power Inc. (PLUG) is up 7% at $4.10 [3] Premarket Losers - Rich Sparkle Holdings Limited (ANPA) has decreased by 15% to $22.10 - CCH Holdings Ltd Ordinary Shares (CCHH) is down 15% at $3.73 - Xcel Brands, Inc. (XELB) has fallen by 14% to $2.04 - Quantum Computing Inc. (QUBT) is down 13% at $21.39 - Rent the Runway, Inc. (RENT) has decreased by 12% to $4.70 - MDJM Ltd (UOKA) is down 11% at $2.96 - CID HoldCo, Inc. (DAIC) has fallen by 9% to $2.72 - Algorhythm Holdings, Inc. (RIME) is down 9% at $2.47 - Corbus Pharmaceuticals Holdings, Inc. (CRBP) has decreased by 8% to $13.50 - Art's-Way Manufacturing Co., Inc. (ARTW) is down 7% at $2.58 [4]

Group 1: Reviva Pharmaceuticals Holdings Inc. (RVPH) - RVPH experienced a significant after-hours rally, increasing 18.27% to $0.58 after a 35.1% surge during regular trading, with a trading volume of over 40.5 million shares, nearly nine times its daily average [2][3] - The company has a market cap of $47 million and is focused on its lead candidate brilaroxazine, which targets neuropsychiatric and respiratory conditions [3] Group 2: Penumbra Inc. (PEN) - PEN surged 7.97% in after-hours trading to $273.69, following a 1.55% gain during the regular session, with a market cap nearing $9.9 billion [4][5] - The company has increased its revenue guidance for FY25 to a range of $1.355 billion - $1.370 billion, indicating a growth of 13% to 15% over 2024 [6] Group 3: Palisade Bio Inc. (PALI) - PALI jumped 10% in after-hours trading to $1.87, extending a 29.8% surge during the regular session, driven by a $138 million public offering [7][8] - The company has a market cap of $15.8 million and is gaining attention due to recent clinical updates and licensing agreements [8] Group 4: IO Biotech Inc. (IOBT) - IOBT rose 5.08% in after-hours trading to $0.4571, following a 22.3% surge during the regular session, with heavy trading volume of 16.7 million shares [9] - The company announced plans to design a new registrational study for its cancer vaccine candidate Cylembio after receiving regulatory feedback from the FDA [10] Group 5: Rallybio Corp. (RLYB) - RLYB increased 11.2% in after-hours trading to $0.5688, reversing a modest dip during the regular session, with a market cap of $21.4 million [11][12] - The company recently completed dosing in its Phase 1 study for RLYB116 and received a $12.5 million milestone payment for progress on the REV102 program [12] Group 6: Vor Biopharma Inc. (VOR) - VOR rose 3.6% in after-hours trading to $38.00, recovering from a 6.6% decline during the regular session, with a market cap of $251 million [13][14] - The company is focusing on its trem-cel platform and CD33-directed therapies for acute myeloid leukemia, alongside new executive appointments [14]

Core Insights - Palisade Bio, Inc. has successfully closed an underwritten public offering, raising approximately $138 million to support the Phase 2 clinical development of PALI-2108 for Ulcerative Colitis [1][2] Group 1: Offering Details - The offering consisted of 197,154,844 shares of common stock priced at $0.70 per share [3] - The offering was led by B Group Capital and Columbia Threadneedle Investments, with participation from several notable investors [1] Group 2: Use of Proceeds - Proceeds from the offering will be utilized to advance the clinical development program for PALI-2108, which targets significant unmet medical needs in inflammatory bowel disease (IBD) [2] Group 3: Company Overview - Palisade Bio is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases [6]

Core Insights - Recent market movements have highlighted significant price changes in several companies, attracting investor attention Company Summaries - **Palisade Bio, Inc. (PALI)**: Experienced an 83.77% price surge to $1.57, supported by a trading volume of 143,677,281. The company raised $120 million through an upsized underwritten public offering, selling 171 million shares at $0.70 each, to advance its novel therapeutics for autoimmune, inflammatory, and fibrotic diseases [1][6] - **Ouster, Inc. (OUSTZ)**: Saw a 76.55% price increase to $0.09, with a volume of 150,580. This reflects growing confidence in Ouster's high-resolution lidar technology, which serves various industries including automotive and robotics [2][6] - **Ryvyl Inc. (RVYL)**: Formerly known as GreenBox POS, experienced a 72.64% price jump to $0.511, supported by a substantial volume of 231,813,941. The company focuses on blockchain-based payment solutions, showcasing resilience and innovation in the technology sector [3] - **Klotho Neurosciences, Inc. (KLTOW)**: Saw a 50.11% price increase to $0.14, with a volume of 134,508. The company is advancing gene therapy product candidates, and its ALS therapy received Orphan Drug Designation from the U.S. FDA, contributing to a rise in shares [4] Industry Overview - The top gainers reflect diverse industries, including biotechnology, healthcare, technology, and financial services, underscoring the dynamic nature of the market and varied investment opportunities [5]

Core Viewpoint - Palisade Bio, Inc. has announced a public offering of 171,440,559 shares of its common stock at a price of $0.70 per share, aiming to raise approximately $120 million in gross proceeds before expenses [1][3]. Group 1: Offering Details - The offering includes a 45-day option for underwriters to purchase an additional 25,714,285 shares at the public offering price [2]. - The expected closing date for the offering is around October 2, 2025, pending customary closing conditions [3]. - A registration statement related to the offering was declared effective by the SEC on September 30, 2025, with an additional statement filed on October 1, 2025 [4]. Group 2: Company Overview - Palisade Bio is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases [6]. - The company aims to transform the treatment landscape through a targeted approach with its therapeutics [6].

Carlsbad, CA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that the Company’s special meeting of stockholders held on September 18, 2025 at 9:00 a.m. Pacific Time was convened and adjourned, without any business being conducted, due to lack of the required quorum. A quorum cons ...

Core Insights - PALI-2108 shows favorable safety profile with no serious adverse events and promising efficacy in ulcerative colitis [1][5] - The Phase 1b study demonstrated a 100% clinical response rate, with significant improvements in various clinical and biomarker measures [2][5] - The drug is positioned as a potential first-in-class therapy for both ulcerative colitis and fibrostenotic Crohn's disease [3][4] Clinical Findings - Phase 1b UC cohort had all patients responding to treatment, with 2 out of 5 achieving remission in just seven days [2][5] - Significant reductions in modified Mayo score (62.8% mean reduction) and histological improvements were observed [5] - Biomarker analyses indicated a reduction in inflammatory markers and normalization of 186 fibrotic gene markers [5] Development Timeline - Patient dosing for the Phase 1b FSCD study is expected to start in the second half of 2025, with Phase 2 IND submissions anticipated in the first half of 2026 [1][6] Mechanism and Design - PALI-2108 is designed for gut-restricted delivery, targeting the terminal ileum and colon, which minimizes systemic exposure and enhances local efficacy [7] - The drug's mechanism supports both anti-inflammatory and anti-fibrotic activities, making it a versatile therapeutic option [4][7] Company Overview - Palisade Bio is focused on developing precision therapies for autoimmune, inflammatory, and fibrotic diseases, aiming to transform treatment landscapes with targeted approaches [8]

Core Insights - Palisade Bio is developing PALI-2108, a first-in-class dual-acting anti-inflammatory and anti-fibrotic therapy for fibrostenotic Crohn's disease (FSCD), which currently has no approved treatments [1][3] - The company received a No Objection Letter from Health Canada for its Clinical Trial Application, allowing it to proceed with a Phase 1b clinical study [1][3] - Patient dosing is expected to begin in the second half of 2025, with topline data anticipated in the first quarter of 2026 [1][2] Company Overview - Palisade Bio is a clinical-stage biopharmaceutical company focused on precision therapies for autoimmune, inflammatory, and fibrotic diseases [5] - The company aims to transform the treatment landscape by developing targeted therapeutics [5] Product Details - PALI-2108 is an orally administered prodrug designed for gut-restricted delivery, targeting the terminal ileum and colon [4] - The drug is activated by bacterial enzymes in the lower intestine, achieving high local tissue concentrations while minimizing systemic exposure [4] - This design aims to enhance anti-inflammatory and anti-fibrotic effects while reducing common side effects associated with systemic PDE4 inhibitors [4] Clinical Study Information - The Phase 1b study will enroll approximately 6-12 patients to evaluate safety, pharmacokinetics (PK), and pharmacodynamics (PD) [2][7] - The study will include monitoring of adverse events, laboratory tests, EKGs, and paired ileal biopsies analyzed by RNA sequencing [7] - Data from this study, along with results from previous trials in ulcerative colitis, will support the planned Phase 2 IND submission to the FDA in the first half of 2026 [3]